Most of the NSCLC molecular markers currently applied in the clinic are broad-spectrum tumor-related markers that lack specificity and sensitivity, for example, serum carcinoembryonic antigens, glyco-antigens, tumor-associated autoantibodies, etc. [4–6]. Here, CEACAM5 is linked to neoplasm.